Press Releases May 27, 2026 07:00 AM

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Harrow to present at William Blair’s Annual Growth Stock Conference highlighting ophthalmic disease management solutions

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
HROW

Harrow, Inc., a Nasdaq-listed company specializing in ophthalmic disease management, announced its management will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The presentation will highlight the company’s portfolio addressing eye diseases and will be webcast live with a replay available for 90 days.

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
HROW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harrow is a leading provider of ophthalmic disease solutions covering conditions like dry eye disease, AMD, cataracts, glaucoma, and more.
  • The company’s management will present at a major growth stock conference to communicate its business strategy and growth prospects.
  • The presentation is accessible via webcast, enhancing investor access and transparency.
  • Impact sectors include healthcare, biotechnology, and pharmaceutical markets focused on eye care and disease management.

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega, Vice President of Investor Relations and Communications
[email protected]
617-913-8890


Risks

  • Dependence on continued innovation and successful commercialization of ophthalmic products.
  • Potential market and competitive pressures in the ophthalmic pharmaceutical and device sector.
  • Regulatory and reimbursement risks inherent in healthcare and pharmaceutical industries affecting product adoption and sales.

More from Press Releases

CLINUVEL’s ADS to commence trading on Nasdaq Jul 20, 2026 EVA LIVE TARGETS A $3 TRILLION GLOBAL DEFENSE, SATELLITE AND AI INFRASTRUCTURE OPPORTUNITY WITH PROPOSED ACQUISITION OF AIRBEAM WIRELESS TECHNOLOGIES Jul 20, 2026 Trump Media Settles Legal Disputes Jul 19, 2026 GEnx-1B Engines Surpass 50 Million Flight Hours Jul 19, 2026 XA Investments President Kimbery Flynn Speaks to Shareholders About XFLT Proxy Vote Jul 19, 2026